Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
To create leading company developing medicines targeting metalloenzymes
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Global pharmaceutical company having a surgical business concept incepted in Dubai
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
The use of procalcitonin testing for sepsis management is highest in the US
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
